Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LTR-Memvaxraleucel
- Development stage
- Unknown
- Lead developer
- APAC Biotech
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
LTR-Memvaxraleucel is an autologous memory T-cell-based immunotherapy developed by APAC Biotech for the treatment of recurrent or metastatic solid tumors. The therapy involves the ex vivo isolation, activation, and expansion of a patient's own central memory (Tcm) and effector memory (Tem) T cells, which are primed to recognize tumor-associated antigens. By leveraging the long-lived, self-renewing, and potent anti-tumor properties of memory T-cell subsets, LTR-Memvaxraleucel aims to provide a sustained and durable immune response against advanced malignancies. This personalized cell therapy is designed to overcome the transient efficacy often observed with conventional T-cell treatments by ensuring the persistence of tumor-reactive cells in the patient's circulation. It is currently being evaluated in Phase 2 clinical trials in India.
- Brand names
- LTR-Memvaxraleucel
02
Targets
Patient-specific tumor-associated and tumor-specific antigen-MHC complex on autologous dendritic cells
Beyond the preview
Go deeper on LTR-Memvaxraleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LTR-Memvaxraleucel.